JHJosef Heine

Josef Heine

*This is an algorithmically generated author record based on publicly available information.

Josef Heine has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy of imidacloprid 10%/moxidectin 1% (Advocate®/Advantage Multi™) against fleas (Ctenocephalides felis felis) on ferrets (Mustela putorius furo)

    by Ulf Wenzel, Josef Heine, Heidrun Mengel, Franziska Erdmann, Roland Schaper, Simon Heine, Arwid Daugschiess

    Ferrets (Mustela putorius furo) are becoming increasingly popular as pets and are kept in households with other pet animals such as dogs and cats, from which they may catch flea infestations with the predominant flea species Ctenocephalides felis. In this study, the efficacy of imidacloprid/moxidectin spot-on (Advocate®/Advantage Multi™) was investigated in the therapy and prevention of flea infestation in ferrets. Sixteen adult ferrets of varying weights and ages and of both sexes were included. Ferrets were infested with 50 fleas each on days −7, −1, 7, 14, 21, and 28. On study day −6, the animals were randomized into two groups based on body weight and flea count. Each ferret allocated to group 1 was treated with 0.4 ml of imidacloprid 10%/moxidectin 1% (Advocate®/Advantage Multi™). The ferrets in group 2 remained untreated. Flea counts were performed by combing 24 to 48 h after infestation. The primary efficacy criterion was the reduction in the number of fleas at each time point post treatment compared to the ferrets in the untreated control group. On day 1, the therapeutic efficacy was 100%. The preventative efficacy was 100% at 1 and 2 weeks post treatment, and it was >97% and >90% at 3 and 4 weeks post treatment. No local or systemic side effects were observed in any of the ferrets treated.


  • Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot–on in the treatment of generalized demodicosis in dogs: results of a European field study

    by J. Heine, K. Krieger, P. Dumont, K. Hellmann

    Efficacy and safety of the test product imidacloprid 10%+moxidectin 2.5% spot on (Advocate®, Advantage multi®) in the treatment of canine generalized demodicosis were evaluated in a multi–centre, controlled, randomized, blinded field study in Albania, France, and Germany. The study was conducted according to a non–inferiority design to demonstrate that the efficacy of the test product is not inferior to that of a control product containing milbemycin oxime (Interceptor, tablets for oral application). Of the 72 dogs enrolled, all of which expressed clinical signs of generalized demodicosis, 63 completed the study. Of these, 30 dogs were treated 2–4 times, at 4–week intervals, with the test product at the recommended dose of at least 0.1 ml/kg body weight. Thirty–three dogs were treated daily for two to four periods of 4 weeks with the control product according to label instructions (0.5–1 or 1–2 mg/kg body weight). Presence of mites in deep skin scrapings and clinical improvement were assessed 3–6 times at each inspection at 4–week intervals. Treatment was discontinued in dogs negative for mites on two subsequent examinations 4weeks apart or at the last examination on day 84. At the end of the trial, dogs in both groups showed a similar clinical improvement. No Demodex mites were detected in 26 of 30 dogs treated with imidacloprid/moxidectin and in 29 of 33 dogs treated with milbemycin oxime. Statistical evaluation confirmed that the efficacy of the test product in the treatment of generalized canine demodicosis was not inferior to that of milbemycin oxime.